Inflammation and cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 8 of the 94 sources its claims cite were checked for support.
Abstract
Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
Overview
CoChat Summary
TL;DR
This review argues that inflammation is a critical component of tumour progression, with inflammatory cells and their mediators fostering proliferation, survival, angiogenesis, invasion and metastasis. It synthesizes evidence linking chronic infection/inflammation to cancer and discusses anti-inflammatory therapeutic opportunities.
Key findings
- Many cancers arise from sites of infection, chronic irritation and inflammation; the tumour microenvironment, largely orchestrated by inflammatory cells, is an indispensable participant in neoplasia, fostering proliferation, survival and migration.
- Upwards of 15% of malignancies worldwide are attributable to infections, a global total of 1.2 million cases per year; chronic inflammatory conditions are associated with neoplasms including colorectal carcinoma in inflammatory bowel disease and gastric cancer with chronic *Helicobacter pylori* infection, the second most common cancer globally.
- In MMTV-PyMT mammary cancer mice crossed with CSF-1-null (*Csf1op*) mice, absence of CSF-1 had no apparent early consequence, but late-stage invasive carcinoma and pulmonary metastases were significantly attenuated; targeting CSF-1 to mammary epithelium restored macrophage recruitment, primary tumour development and metastatic potential.
- Long-term aspirin/NSAID use reduces colon cancer risk by 40–50% and may be preventative for lung, oesophagus and stomach cancer; tumour cells also co-opt innate immune signalling molecules such as selectins, chemokines and their receptors for invasion, migration and metastasis.
Methods
- Narrative review; no primary experiments or new patient/animal data are reported.
- Synthesizes published literature on inflammation, innate immunity, wound healing, inflammatory cell types, chemokines, chronic inflammation-associated cancers, selectin/MMP biology and anti-inflammatory therapy.
- Main analysis is conceptual synthesis and interpretation of cited studies; no systematic search strategy, inclusion criteria or quantitative meta-analysis is described.
Limitations
- The paper states that the acquired immune response to cancer is intimately related to the inflammatory response but is beyond the scope of the article.
- Evident from the text: as a narrative review, it lacks a systematic search or formal evidence appraisal, and conclusions depend on the cited studies.
- Evident from the text: many molecular and cellular mechanisms mediating the inflammation–cancer relationship remain unresolved, and therapeutic implications are largely based on observational, animal or preclinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 66 Not checked · 35 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to altering the local balance of pro-angiogenic factors during melanoma development, during human cervical carcinogenesis, TAMs express VEGF-C and VEGF-D as well as the VEGF receptor-3 (VEGFR-3), all of which are implicated in formation of lymphatic vessels and lymphatic metastases17.”
What the sources say
- Supportedcites [17] Schoppmann S, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947–956. doi: 10.1016/S0002-9440(10)64255-1. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Abstract (p.1) states that in human cervical cancers the VEGF-C- and VEGF-D-producing stromal cells were identified in situ as a subset of activated TAMs (CD68, CD23, CD14) that 'also expressed the VEGF-C-and VEGF-D-specific tyrosine kinase receptor VEGFR-3'. The Discussion reinforces this: 'All VEGF-C-and VEGF-D-producing TAMs co-expressed also the corresponding tyrosine kinase receptor VEGFR-3', and links their density to peritumoral lymphatic microvessel density, lymphangiosis carcinomatosa and lymph-node metastasis, i.e. lymphatic vessel formation and lymphatic spread. The melanoma clause of the citing sentence belongs to a different citation and was not judged here. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tumour cells produce various cytokines and chemokines that attract leukocytes.”
What the sources say
- Could not verifycites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Helicobacter pylori section (p. 9) describes white blood cells being attracted during inflammation, followed by increased cytokine production. The Mechanisms section (p. 2) discusses inflammation caused by infection. Neither passage says that tumour cells produce cytokines or chemokines to attract leukocytes; searches for those terms found no supporting passage. (LLM, conf=0.76)
- Partly supportedcites [12] Wahl LM, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst. 1998;90:1583–1584. doi: 10.1093/jnci/90.21.1583. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
On p. 1, the paper says tumor-derived attractants, including monocyte chemotactic protein-1, recruit tumor-associated macrophages to tumors. It also lists several tumor-derived cytokines, but describes them as reducing macrophage cytotoxicity, not attracting leukocytes. The claim extends the recruitment point beyond the macrophages and attractant discussed in the paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The key difference between PyMT mice and PyMT/Csf1op/Csf1op mice is not in the apparent proliferative capacity of neoplastic epithelial cells, but in the failure to recruit mature macrophages into neoplastic tissue in the absence of CSF-1.”
What the sources say
- Supportedcites [21] Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–740. doi: 10.1084/jem.193.6.727. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Introduction reports that CSF-1 deficiency did not affect primary mammary tumor growth but delayed macrophage recruitment. The Results section (“Absence of CSF-1 Does Not Effect Growth of the Primary Mammary Tumor”) found no significant difference in tumor-cell proliferation, and the Discussion reports no macrophage infiltration at the tumor site in CSF-1-null PyMT mice. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
What the sources say
- Partly supportedcites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Mechanisms section (p. 2) says inflammatory phagocytes produce reactive oxygen and nitrogen species that can favor carcinogenesis. The H. pylori section (p. 9) links recruited white blood cells and cytokines to oxidative DNA damage. Neither passage establishes the claimed contribution of all four named cell types through extracellular proteases, pro-angiogenic factors, and chemokines, or cites genetic and functional experiments for it. (LLM, conf=0.78)
- Not checked yetcites [23] DiCarlo E, et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97:339–345. doi: 10.1182/blood.v97.2.339. [DOI] [PubMed] [Google Scholar] source
- Partly supportedcites [24] Coussens LM, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382–1397. doi: 10.1101/gad.13.11.1382. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) links mast cells to angiogenesis during premalignant squamous carcinogenesis through the release of pro-angiogenic proteases. The paper does not establish the claimed roles of neutrophils, eosinophils or activated T lymphocytes, or their release of chemokines. (LLM, conf=0.86)
- Not checked yetcites [25] Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490. doi: 10.1016/s0092-8674(00)00139-2. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Partly supportedcites [26] Bergers G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2000;2:737–744. doi: 10.1038/35036374. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies mast cells and neutrophils as suppliers of MMP-9 in a model of squamous carcinogenesis, and reports that MMP-9 can mobilize VEGF during angiogenesis. Our copy does not establish the claimed roles for eosinophils or activated T lymphocytes, or say that these cells contribute by releasing chemokines. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“Indeed, macrophage infiltration is closely associated with the depth of invasion of primary melanoma due, in part, to macrophage-regulated tumour-associated angiogenesis19.”
What the sources say
- Not checked yetcites [19] Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 1999;43:S69–S71. doi: 10.1007/s002800051101. [DOI] [PubMed] [Google Scholar] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims
Create a free account to see all 107 claims and to verify the 86 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation is also important for carcinogenesis, as pro-inflammatory cytokines, including IL-1β, can be tumour promoting6,111.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammatory cells such as macrophages and neutrophils can cause immunosuppression in the TME.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citationMatrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Self-citationThe Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410 · cited 1×
“A family of chemotactic cytokines, named chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leukocyte population”
Cited by
Items 1,101–1,179 of 1,179
Increased mTOR activation in idiopathic multicentric Castleman disease
Arenas, D. J., Floess, K., Kobrin, D., Pai, R.-A. L., Srkalovic, M. B., Tamakloe, M.-A., Rasheed, R., Ziglar, J., Khor, J., Parente, S. A. T., et al. (2020) · Blood · doi:10.1182/blood.2019002792 · Cited by 83
“Age, y; mean (range) 30 (1-65) 38 (17-67) 46 (30-62)”
Review of Mesenchymal Stem Cells and Tumors: Executioner or Coconspirator?
Feng, B., & Chen, L. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0652 · Cited by 83
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration
Drucker, C., Gewiese, J., Malchow, S., Scheller, J., & Rose-John, S. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.003 · Cited by 83
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Fontana, L. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2008.04.005 · Cited by 81
Role of epigenetics in transformation of inflammation into colorectal cancer
Yang, Z.-H., Dang, Y.-Q., & Ji, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2863 · Cited by 81
An Insight into the Anticancer Effects of Fermented Foods: A Review
Tasdemir, S. S., & Sanlier, N. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104281 · Cited by 77
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“The TME is also characterized by chronic inflammation, which is linked to tumor cell proliferation, survival, and metastasis [94].”
Barrera, I., & Spiegel, D. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.864259 · Cited by 75
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
Cole, S. W., Mendoza, S. P., & Capitanio, J. P. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181aa95a9 · Cited by 74
Liang, J., Hänsch, G. M., Hübner, K., & Samstag, Y. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.006 · Cited by 72
Hiraku, Y., Tabata, T., Ma, N., Murata, M., Ding, X., & Kawanishi, S. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00497.x · Cited by 71
Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome
Gupte, A. A., Sabek, O. M., Fraga, D., Minze, L. J., Nishimoto, S. K., Liu, J. Z., Afshar, S., Gaber, L., Lyon, C. J., Gaber, A. O., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1430 · Cited by 70
Sliz, E., Kalaoja, M., Ahola-Olli, A., Raitakari, O., Perola, M., Salomaa, V., Lehtimäki, T., Karhu, T., Viinamäki, H., Salmi, M., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105965 · Cited by 60
Mesothelium and Malignant Mesothelioma
Hiriart, E., Deepe, R., & Wessels, A. (2019) · Journal of Developmental Biology · doi:10.3390/jdb7020007 · Cited by 66
Eksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.21 · Cited by 66
Linking anemia to inflammation and cancer: The crucial role of TNFα
Buck, I., Morceau, F., Grigorakaki, C., Dicato, M., & Diederich, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.018 · Cited by 66
“Clinical trials established erythropoietin’s ability to incr ease hemoglobin levels and reduce transfusion requirements [2, 3].”
TGFβ and cancer metastasis: an inflammation link
Yang, L. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9226-3 · Cited by 65
A positive feedback loop of IL-17B-IL-17RB activates ERK/β-catenin to promote lung cancer metastasis
Yang, Y.-F., Lee, Y.-C., Lo, S., Chung, Y.-N., Hsieh, Y.-C., Chiu, W.-C., & Yuan, S.-S. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.037 · Cited by 52
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
Zhang, J., Fu, L., Shen, B., Liu, Y., Wang, W., Cai, X., Kong, L., Yan, Y., Meng, R., Zhang, Z., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.08.010 · Cited by 63
Parasite-Produced MIF Cytokine: Role in Immune Evasion, Invasion, and Pathogenesis
Ghosh, S., Jiang, N., Farr, L., Ngobeni, R., & Moonah, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01995 · Cited by 62
Yamagishi, T., Fujimoto, N., Nishi, H., Miyamoto, Y., Hara, N., Asano, M., Fuchimoto, Y., Wada, S., Kitamura, K., Ozaki, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.014 · Cited by 61
Zhu, L.-Q., Zhang, L., Zhang, J., Chang, G.-L., Liu, G., Yu, D.-D., Yu, X.-M., Zhao, M.-S., & Ye, B. (2021) · Journal of Integrative Medicine · doi:10.1016/j.joim.2020.11.001 · Cited by 60
Lin, H.-T. V., Lu, W.-J., Tsai, G.-J., Chou, C.-T., Hsiao, H.-I., & Hwang, P.-A. (2016) · Process Biochemistry · doi:10.1016/j.procbio.2016.08.024 · Cited by 59
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Guo, J., Chen, S., Chen, Y., Li, S., & Xu, D. (2018) · Cancer Management and Research · doi:10.2147/cmar.s156071 · Cited by 54
Kluza, E., Yeo, S. Y., Schmid, S., van der Schaft, D. W. J., Boekhoven, R. W., Schiffelers, R. M., Storm, G., Strijkers, G. J., & Nicolay, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.031 · Cited by 54
ZHANG, P., DONG, L., YAN, K., LONG, H., YANG, T.-T., DONG, M.-Q., ZHOU, Y., FAN, Q.-Y., & MA, B.-A. (2013) · Oncology Reports · doi:10.3892/or.2013.2619 · Cited by 54
Hiramatsu, S., Tanaka, H., Nishimura, J., Sakimura, C., Tamura, T., Toyokawa, T., Muguruma, K., Yashiro, M., Hirakawa, K., & Ohira, M. (2018) · BMC Immunology · doi:10.1186/s12865-018-0251-2 · Cited by 53
Fan, S., Tang, J., Li, N., Zhao, Y., Ai, R., Zhang, K., Wang, M., Du, W., & Wang, W. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0077-8 · Cited by 48
IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells
Broderick, L., Brooks, S. P., Takita, H., Baer, A. N., Bernstein, J. M., & Bankert, R. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.09.008 · Cited by 47
Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages
Almouazen, E., Bourgeois, S., Boussaïd, A., Valot, P., Malleval, C., Fessi, H., Nataf, S., & Briançon, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.025 · Cited by 47
Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis
Levy, C., & Martin, E. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608655 · Cited by 46
Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Non-Small-Cell Lung Cancer
Guo, M., Sun, T., Zhao, Z., & Ming, L. (2021) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.20-00090 · Cited by 46
The Prognostic Value of Platelet-to-Lymphocyte Ratio in Urological Cancers: A Meta-Analysis
Li, D.-Y., Hao, X.-Y., Ma, T.-M., Dai, H.-X., & Song, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15673-2 · Cited by 44
Brimson, J. M., Onlamoon, N., Tencomnao, T., & Thitilertdecha, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109319 · Cited by 44
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., Omri, H. E., Bhat, A. A., & Uddin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145002 · Cited by 44
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
Harris, R., Beebe, & Alshafie (2012) · Journal of Experimental Pharmacology · doi:10.2147/jep.s23826 · Cited by 43
Biomarkers for simplifying HTS 3D cell culture platforms for drug discovery: the case for cytokines
Lai, Y., Asthana, A., & Kisaalita, W. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.009 · Cited by 43
Boudreau, A., van't Veer, L. J., & Bissell, M. J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20880 · Cited by 43
Mangsbo, S. M., Sanchez, J., Anger, K., Lambris, J. D., Ekdahl, K. N., Loskog, A. S., Nilsson, B., & Tötterman, T. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902374 · Cited by 42
Nestares, T., Martín-Masot, R., Labella, A., Aparicio, V. A., Flor-Alemany, M., López-Frías, M., & Maldonado, J. (2020) · Nutrients · doi:10.3390/nu12030844 · Cited by 41
“In CD, it is known that there is an uncontrolled activation of the proinflammatory pathway [37] that maintains the production of free radicals that causes oxidative stress through the increase of reactive oxygen species and consequent damage to cellular DNA [38], and it has been documented that chronic inflammation ma…”
BackgroundCapone, F., Guerriero, E., Sorice, A., Colonna, G., Ciliberto, G., & Costantini, S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3064643 · Cited by 38
Abdallah, M., Marzocco, S., Adesso, S., Zarrouk, M., & Guerfel, M. (2018) · Acta Histochemica · doi:10.1016/j.acthis.2017.10.005 · Cited by 35
Gelaleti, G. B., Borin, T. F., Maschio-Signorini, L. B., Moschetta, M. G., Jardim-Perassi, B. V., Calvinho, G. B., Facchini, M. C., Viloria-Petit, A. M., & de Campos Zuccari, D. A. P. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.013 · Cited by 35
Skin Regenerative and Anti-Cancer Actions of Copper Peptides
Pickart, L., & Margolina, A. (2018) · Cosmetics · doi:10.3390/cosmetics5020029 · Cited by 33
Mitochondrial epigenetics regulating inflammation in cancer and aging
Chatterjee, D., Das, P., & Chakrabarti, O. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.929708 · Cited by 33
“Interestingly, the inflammatory signalling pathway comprising IL-6 and STAT3 molecules have been implicated in stomach, colorectal, bladder and lung cancers (Coussens and Werb, 2002).”
BackgroundPérez-Ramírez, C., Cañadas-Garre, M., Alnatsha, A., Villar, E., Delgado, J. R., Faus-Dáder, M. J., & Calleja-Hernández, M. Ÿ. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.002 · Cited by 33
Deficient inflammatory response to UV radiation in neonatal mice
Wolnicka-Glubisz, A., Damsker, J., Constant, S., Corn, S., De Fabo, E., & Noonan, F. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206729 · Cited by 32
The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer
Xu, W., Liu, H., Song, J., Fu, H.-X., Qiu, L., Zhang, B.-F., Li, H.-Z., Bai, J., & Zheng, J.-N. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1500-7 · Cited by 31
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
MicroRNAs: a symphony orchestrating evolution and disease dynamics
Quah, S., Subramanian, G., Tan, J. S. L., Utami, K. H., & Sampath, P. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.07.004 · Cited by 31
IL-17A-producing T cells are associated with the progression of lung adenocarcinoma
Bao, Z., Lu, G., Cui, D., Yao, Y., Yang, G., & Zhou, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4837 · Cited by 30
Cell resilience in species life spans: a link to inflammation?
Finch, C. E., Morgan, T. E., Longo, V. D., & De Magalhaes, J. P. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00578.x · Cited by 29
Psychosocial Influences in Oncology: An Expanded Model of Biobehavioral Mechanisms
LUTGENDORF, S. K., COSTANZO, E. S., & SIEGEL, S. D. (2007) · Psychoneuroimmunology · doi:10.1016/b978-012088576-3/50048-4 · Cited by 28
Xu, C.-X., Jin, H., Chung, Y.-S., Shin, J.-Y., Lee, K.-H., Beck, G. R., Palmos, G. N., Choi, B.-D., & Cho, M.-H. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf801578x · Cited by 24
Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men
Dawson, K., Zhao, L., Adkins, Y., Vemuri, M., Rodriguez, R. L., Gregg, J. P., Kelley, D. S., & Hwang, D. H. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.004 · Cited by 24
Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival
Spreafico, A., Coate, L., Zhai, R., Xu, W., Chen, Z.-F., Chen, Z., Patel, D., Tse, B., Brown, M. C., Heist, R. S., et al. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2016.11.009 · Cited by 19
Kataki, M. S., Kakoti, B. B., Bhuyan, B., Rajkumari, A., & Rajak, P. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60029-7 · Cited by 22
Williams, L. A., Haynes, D., Sample, J. M., Lu, Z., Hossaini, A., McGuinn, L. A., Hoang, T. T., Lupo, P. J., & Scheurer, M. E. (2024) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djae035 · Cited by 22
Mirata, S., Almonti, V., Di Giuseppe, D., Fornasini, L., Raneri, S., Vernazza, S., Bersani, D., Gualtieri, A. F., Bassi, A. M., & Scarfì, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052840 · Cited by 21
Wang, N., Gaddam, S., Wang, L., Xie, Y., Fan, Z., Yang, W., Tuli, R., Lo, S., Hendifar, A., Pandol, S., et al. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28167 · Cited by 21
Molimau-Samasoni, S., Woolner, V. H., Foliga, S. T., Robichon, K., Patel, V., Andreassend, S. K., Sheridan, J. P., Te Kawa, T., Gresham, D., Miller, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100880118 · Cited by 20
Macer-Wright, J. L., Stanley, N. R., Portman, N., Tan, J. T., Bursill, C., Rayner, B. S., & Hawkins, C. L. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00044 · Cited by 18
Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
Iovanna, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100965 · Cited by 18
Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators
Serhal, R., Hilal, G., Boutros, G., Sidaoui, J., Wardi, L., Ezzeddine, S., & Alaaeddine, N. (2015) · BioMed Research International · doi:10.1155/2015/850246 · Cited by 18
Inflammation Through a Psychoneuroimmunological Lens
Bennett, J. M., Gillie, B. L., Lindgren, M. E., Fagundes, C. P., & Kiecolt-Glaser, J. K. (2013) · Handbook of Systems and Complexity in Health · doi:10.1007/978-1-4614-4998-0_19 · Cited by 15
Zhou, Y., Luo, Y., Liang, H., Zhong, P., & Wu, D. (2023) · BMC Neurology · doi:10.1186/s12883-023-03365-6 · Cited by 11
(2023) · doi:10.21203/rs.3.rs-2657629/v1 · Cited by 11
Serum zonulin and colorectal cancer risk
Marino, M., Mignozzi, S., Michels, K. B., Cintolo, M., Penagini, R., Gargari, G., Ciafardini, C., Ferraroni, M., Patel, L., Del Bo’, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76697-z · Cited by 10
Skogstad, M., Lunde, L.-K., Ulvestad, B., Aass, H., Clemm, T., Mamen, A., & Skare, Ø. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15020264 · Cited by 9
Millikin, R. J., Raja, K., Steill, J., Lock, C., Tu, X., Ross, I., Tsoi, L. C., Kuusisto, F., Ni, Z., Livny, M., et al. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05539-y · Cited by 9
Sun, J., Dong, Y., Wang, D., Yang, Y., Zhou, Z., Zhu, M., Wang, T., & Teng, L. (2024) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2023.102493 · Cited by 5
Pickart, L., & Margolina, A. (2021) · OBM Genetics · doi:10.21926/obm.genet.2102128 · Cited by 3
An inflammation self-adaptive nanocarrier for highly efficient gene therapy
Jia, H., Yang, Y., Li, M., Li, Y., Han, X., Li, J., Zhang, X., Fan, C., Wu, T., Cui, C., et al. (2020) · Materials Today Chemistry · doi:10.1016/j.mtchem.2020.100287 · Cited by 3
Zaina (2014) · doi:10.1097/mol.0000000000000075 · Cited by 1
Distinct affinity of nuclear proteins to the surface of chrysotile and crocidolite
Kubo, Y., Takenaka, H., Nagai, H., & Toyokuni, S. (2012) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.12-39
Metadata
- Authors
- Coussens, L. M., & Werb, Z.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature
- Published
- 2002-12
- Volume
- 420
- Issue
- 6917
- Pages
- 860-867
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2803035
- OpenAlex
- W1965037168
- Cited by
- 15,111
- References
- 88
- Citations by year
- 2026: 328 · 2025: 590 · 2024: 701 · 2023: 849 · 2022: 873 · 2021: 934 · 2020: 858 · 2019: 827 · 2018: 742 · 2017: 775 · 2016: 756 · 2015: 773 · 2014: 776 · 2013: 749 · 2012: 689
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- V Foundation for Cancer Research
- Edward Mallinckrodt, Jr. Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- inflammation, cancer, tumor microenvironment, tumor progression, chronic inflammation, infection-associated cancer, inflammatory cells, tumor cell proliferation, cell migration, metastasis, innate immune signaling, selectins, chemokines, chemokine receptors
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Leukocytes, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Disease Progression, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.